ReviewJournal of current ophthalmology
Use of Mitomycin C in Ophthalmic Surgery.
Review in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- From Fabrication to Function: Scalable Spray-Assisted Layer-by-Layer Films for Drug Delivery in Glaucoma.International journal of molecular sciences · 2026Article
- Glaucoma Filtration Surgery in Rabbit Pre-Clinical Models: Design, Drug Dosing and Reporting Practices 2011-2025.Vision (Basel, Switzerland) · 2026Review
- Quercetin Sensitizes Retinoblastoma Cells to Mitomycin C Through Transcriptional Modulation of p53-Regulated Apoptotic Genes: A Preclinical Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Efficacy of Intraoperative 9-0 Nylon Thread Insertion for Preventing Hypotony-Related Complications Following PreserFlo MicroShunt Implantation in Japanese Patients: A Comparative Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Amniotic Membrane in Excimer Laser Surface Ablation (ELSA): Mechanisms for Haze Prevention and Broader Ocular Surface Optimisation.Ophthalmology and therapy · 2026Review
- Off-label prescribing in ophthalmology: a retrospective analysis.Frontiers in pharmacology · 2026Article
- Real-world safety profile of mitomycin: signal detection and time-to-onset analysis from FDA adverse event reporting system and VigiAccess databases.International journal of clinical pharmacy · 2025Article
- Safety and Efficacy of Preserflo Microshunt in Different Subtypes of Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To discuss the application of mitomycin C (MMC) in ophthalmic surgical procedures, including dosage, method of application, reported complications, and follow-up results. Methods: A comprehensive literature search was conducted on PubMed, Google Scholar, and the Cochrane Library without date limitations using keywords: mitomycin, ophthalmic, and surgery. The original articles used as references were first graded using a 0 to 5 grading scale devised by the authors to ensure the uniformity of reference selection. Only those original articles grading 3 or above based on this grading scale were used as references. The last search was conducted in March 2024. Results: MMC has been widely utilized in ophthalmic surgery due to its effects on the wound-healing process. The main current applications include pterygium surgery, glaucoma filtering surgery, surgical treatment of ocular surface tumors, eye alignment surgeries, dacryocystorhinostomy, and corneal refractive surgery. Conclusions: The dosage and duration of MMC application in ophthalmic surgery depend on the specific procedure, with ongoing controversies regarding the optimal dosage. In addition, it is essential to consider complications when evaluating the cost-benefit of MMC use. Further randomized clinical trials with larger sample sizes and longer follow-up periods are warranted, with a specific focus on reducing long-term side effects, refining dosage guidelines, and exploring MMC's role in combination therapies for various ophthalmic procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.